




Arrowhead Pharmaceuticals, Inc.
Investor Relations Department
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARWR

Last Trade:	5.57
Trade Time:	4:00 PM ET Feb 16, 2018
Change:	-0.26  (-4.460%)
Day Range	5.46 - 5.95
52-Week Range	1.42 - 6.75
Volume	1,198,951


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 15, 2018*
[Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT](#)
- Feb 15, 2018*
[Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B](#)
- Feb 9, 2018*
[Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results](#)
- Feb 2, 2018*
[Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results](#)
- Jan 22, 2018*
[Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of \\$60.4 Million](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Dec 12, 2017*
[Annual Report \(10-K\)](#)
- Jan 25, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Feb 9, 2018*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)